What targeted therapies are available for Brain Cancer

Targeted Therapies for Brain Cancer

I'll walk you through the targeted therapy landscape for brain cancer, which has expanded significantly in recent years. This is an important area because targeted therapies work differently than traditional chemotherapy—they attack specific genetic mutations that drive your cancer.

How Doctors Think About Targeted Therapy for Brain Cancer

According to the Musella Foundation's Brain Tumor Guide, oncologists now recognize that most high-grade brain cancers have 3 or more actionable mutations—genetic changes that can be targeted with specific drugs. Nearly half of glioblastomas (GBMs) have alterations in DNA-damage repair genes, which opens up treatment possibilities.

The clinical reasoning works like this:

1. Identify the mutation - Your tumor tissue is tested to find specific genetic changes
2. Match to therapy - Doctors look for FDA-approved drugs or clinical trials that target that specific mutation
3. Combine strategically - Targeted therapies are often combined with other treatments like immunotherapy or radiation

FDA-Approved Targeted Therapies for Brain Tumors

According to the Musella Foundation, here are key FDA-approved targeted options:

For Specific Genetic Conditions:

• Belzutifan (Welireg) - Approved August 2021 for brain/spinal cancers linked to Von Hippel-Lindau (VHL) disease, including hemangioblastomas
• Afinitor (Everolimus) - Approved for subependymal giant cell astrocytomas in patients with tuberous sclerosis (approved August 2012)
• Bevacizumab (Avastin) - Approved May 2009 for recurrent glioblastoma in adults

Emerging Targeted Approaches

The NCCN Guidelines for Central Nervous System Cancers describe several targeted therapy strategies that are showing promise:

BRAF/MEK Inhibitor Combinations (for melanoma brain metastases):

• The COMBI-MB trial showed that combining dabrafenib (BRAF inhibitor) with trametinib (MEK inhibitor) produced intracranial responses in 56-59% of patients with brain metastases
• Vemurafenib is another BRAF inhibitor option supported by clinical evidence

TRK Inhibitors (for NTRK gene fusion-positive tumors):

• Larotrectinib and entrectinib have shown activity in brain metastases from NTRK-positive solid tumors

ALK and EGFR-Targeted Therapies (for lung cancer brain metastases):

• These are used for patients whose lung cancer has specific mutations

Advanced Genomic Testing: The Key to Finding Your Options

Here's what's crucial: You need genomic testing of your tumor tissue to know which targeted therapies might work for you. According to the Musella Foundation, the latest anti-cancer therapies are "directed at the genetic DNA mutations that underlie the development and progression of brain cancer."

The testing process identifies:

• Driver mutations - The main genetic changes causing your cancer
• Actionable mutations - Changes that have drugs available to target them
• Passenger mutations - Changes that aren't driving the cancer

Personalized Vaccine Approaches

An emerging targeted approach is personalized cancer vaccines. According to Dr. [removed] Biskup's webinar on personalized vaccines, this involves:

• Sequencing your tumor's DNA and RNA
• Identifying unique mutations (neoantigens) specific to YOUR cancer
• Creating a custom vaccine with 20 peptides targeting those mutations
• Cost: approximately $10,000-$20,000 for diagnosis, up to $60,000 for manufacturing and treatment

This approach is still largely in clinical trials but represents a new frontier in personalized medicine.

Important Questions to Ask Your Oncology Team

Since targeted therapy selection is highly individualized, here are specific questions:

1. "Has my tumor tissue been tested for genetic mutations? If not, can we do comprehensive genomic testing?"
2. "Based on my specific mutations, which FDA-approved targeted therapies are options for me?"
3. "Are there clinical trials available for targeted therapies that match my tumor's genetic profile?"
4. "How would targeted therapy be combined with other treatments like chemotherapy, radiation, or immunotherapy?"
5. "What is the expected response rate and duration of response for the targeted therapy you're recommending?"

Key Resources for Learning More

The Musella Foundation emphasizes that you should access their Patient Navigation Program (in partnership with xCures and Cancer Commons), which uses AI to analyze your [ID removed] and provide a personalized list of treatment options with the rationale for each suggestion—at no cost to you.

Additionally, virtualtrials.org has extensive sections on specific brain tumor treatments, including the latest targeted therapy options.

The Bottom Line

Targeted therapies represent a major advance in brain cancer treatment because they're designed to attack the specific genetic vulnerabilities of YOUR cancer. However, the options available depend entirely on what mutations your tumor has. This is why comprehensive genomic testing is so important—it's the roadmap to finding the right targeted therapy for your situation.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.